<DOC>
	<DOCNO>NCT01010503</DOCNO>
	<brief_summary>This open-label , single-arm , non-randomized study evaluate adherence persistence tocilizumab therapy patient moderate severe active rheumatoid arthritis , inadequate clinical response non-biologic DMARDs . Patients receive tocilizumab 8 mg/kg intravenous infusion every 4 week combination methotrexate case intolerance methotrexate monotherapy . The anticipated time study treatment 6 month . The target sample size 20-50 patient .</brief_summary>
	<brief_title>A Study Tocilizumab With Without Methotrexate Patients With Rheumatoid Arthritis .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient &gt; /= 18 year age moderate severe active rheumatoid arthritis inadequate response , intolerance previous therapy one traditional DMARDs DAS &gt; 3.6 pneumology examination ( include chest xray quantiferon ) &lt; 18 year age active infection active tuberculosis uncontrolled hyperlipoproteinaemia demyelinate disorder concomitant antiTNF drug history intestinal ulceration diverticulitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>